These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 21625416)
1. Development of oral immunomodulatory agents in the management of multiple sclerosis. Nicholas R; Giannetti P; Alsanousi A; Friede T; Muraro PA Drug Des Devel Ther; 2011; 5():255-74. PubMed ID: 21625416 [TBL] [Abstract][Full Text] [Related]
2. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
3. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. Gold R CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693 [TBL] [Abstract][Full Text] [Related]
17. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Thöne J; Ellrichmann G Drug Healthc Patient Saf; 2013; 5():37-47. PubMed ID: 23459383 [TBL] [Abstract][Full Text] [Related]
18. Teriflunomide for oral therapy in multiple sclerosis. Papadopoulou A; Kappos L; Sprenger T Expert Rev Clin Pharmacol; 2012 Nov; 5(6):617-28. PubMed ID: 23234322 [TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809 [TBL] [Abstract][Full Text] [Related]
20. Established and novel disease-modifying treatments in multiple sclerosis. Cross AH; Naismith RT J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]